We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Zohur
Miah
nafldbioresource@uhb.nhs.uk
Dr
Philip
Newsome
p.n.newsome@bham.ac.uk
More information about this study, what is involved and how to take part can be found on the study website.
Diseases of liver
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
NAFLD (Non-alcoholic Fatty Liver Disease), defined as the accumulation of excess fat in the liver, is now the commonest cause of liver disease in Western countries and affects approximately 30-40% of the UK population. Data suggest that NAFLD progresses to NASH (Non-alcoholic steatohepatitis) in about 20% of cases of which 20–25% may progress on to more advanced stages of hepatic fibrosis and cirrhosis, although predicting which individual patients will progress to develop advanced fibrosis is challenging.
Weight loss, as part of lifestyle change, is the only recommended intervention, with a > 10% loss associated with an improvement in fibrosis. As attaining and sustaining weight loss is difficult there have also been concerted efforts to develop pharmacological therapies for patients with NASH. A major challenge has been slow recruitment to clinical trials due to the lack of recallable databases. Patient factors including genotyping/phenotyping will play an ever-more significant role in optimising the choice of pharmacotherapy for patients.
Working with the NIHR Bioresource, we are proposing to develop a centralised national recallable BioResource up to 7500 patients with NAFLD to support scientific and clinical NAFLD research.
KEY AIMS
1) To characterise novel clinical and genetic phenotypes across NAFLD
2) To investigate impact and interaction of co-morbidities across NAFLD
3) To understand the natural history of NAFLD in the UK
SECONDARY AIMS
4) To collect and store blood (for DNA extraction, plasma, serum and other biological components storage) as well as clinical and health and lifestyle data from up to 7,500 participants who have been diagnosed with NAFLD
5) Create a resource of recallable volunteers to help with future research, by obtaining consent from participants that they agree to be approached in the future and invited to further studies.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Participants must not meet any of the below exclusion criteria: 1. Refusal or inability (lack of capacity) to give informed consent. 2. Participants not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Philip
Newsome
p.n.newsome@bham.ac.uk
Zohur
Miah
nafldbioresource@uhb.nhs.uk
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST and funded by NIHR Cambridge Biomedical Research Centre .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 43503
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
